智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属山东信谊制药有限公司(简称“山东信谊”)收到国家药品监督管理局颁发的《药品补充申请批准通知书》(通知书编号：2026B02904)，其同意将盐酸曲唑酮片上市许可持有人变更为山东信谊制药有限公司。
盐酸曲唑酮片是河北龙海药业股份有限公司于2025年在中国批准上市的产品，适用于抑郁症的治疗，对伴有或不伴有焦虑的患者均有效。2026年5月，山东信谊就该药品上市许可持有人变更向国家药监局提出注册上市申请并获批准。截至公告日，公司针对该药品已投入约人民币520万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.